Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.

Lu H, Villafane N, Dogruluk T, Grzeskowiak CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, Kim YW, Creighton CJ, Verhaak RG, Mills GB, Park PJ, Kucherlapati R, Scott KL.

Cancer Res. 2017 Jul 1;77(13):3502-3512. doi: 10.1158/0008-5472.CAN-16-2745. Epub 2017 May 16.

2.

Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.

Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister SM.

Acta Neuropathol. 2011 Jun;121(6):763-74. doi: 10.1007/s00401-011-0817-z. Epub 2011 Mar 20.

PMID:
21424530
3.

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W.

Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi: 10.1158/1078-0432.CCR-13-1746.

4.

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.

Kim HS, Jung M, Kang HN, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC.

Oncogene. 2017 Jun 8;36(23):3334-3345. doi: 10.1038/onc.2016.486. Epub 2017 Jan 16.

PMID:
28092667
5.

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.

Tomić TT, Olausson J, Wilzén A, Sabel M, Truvé K, Sjögren H, Dósa S, Tisell M, Lannering B, Enlund F, Martinsson T, Åman P, Abel F.

PLoS One. 2017 Apr 27;12(4):e0175638. doi: 10.1371/journal.pone.0175638. eCollection 2017. Erratum in: PLoS One. 2017 Sep 7;12 (9):e0184715.

6.

Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.

Iyama K, Matsuse M, Mitsutake N, Rogounovitch T, Saenko V, Suzuki K, Ashizawa M, Ookouchi C, Suzuki S, Mizunuma H, Fukushima T, Suzuki S, Yamashita S.

Thyroid. 2017 Jun;27(6):811-818. doi: 10.1089/thy.2016.0673. Epub 2017 Apr 25.

PMID:
28351223
7.

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.

Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP.

Oncogene. 2009 May 21;28(20):2119-23. doi: 10.1038/onc.2009.73. Epub 2009 Apr 13.

8.

Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.

Wang L, Busam KJ, Benayed R, Cimera R, Wang J, Denley R, Rao M, Aryeequaye R, Mullaney K, Cao L, Ladanyi M, Hameed M.

J Mol Diagn. 2017 May;19(3):387-396. doi: 10.1016/j.jmoldx.2016.11.005.

9.

An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.

Heard JJ, Phung I, Potes MI, Tamanoi F.

BMC Cancer. 2018 Jan 10;18(1):69. doi: 10.1186/s12885-017-3938-5.

10.

Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.

Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, Pichler M, Richtig E.

Br J Dermatol. 2017 Oct;177(4):936-944. doi: 10.1111/bjd.15436. Epub 2017 Sep 4. Review.

PMID:
28278349
11.

MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential.

Jeuken JW, Wesseling P.

J Pathol. 2010 Dec;222(4):324-8. doi: 10.1002/path.2780. Erratum in: J Pathol. 2011 Feb;223(3):446.

PMID:
20976706
12.

The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.

Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C.

Genes Dev. 2012 Sep 1;26(17):1945-58. doi: 10.1101/gad.193458.112. Epub 2012 Aug 14.

13.

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.

Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S.

Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.

14.

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5957-62. doi: 10.1073/pnas.1219232110. Epub 2013 Mar 26. Erratum in: Proc Natl Acad Sci U S A. 2013 May 21;110(21):8750.

15.

Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.

Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, Suri V, Sharma MC, Suri A, Sarkar C.

Cancer Genet. 2015 Mar;208(3):91-5. doi: 10.1016/j.cancergen.2015.01.009. Epub 2015 Feb 20.

PMID:
25794445
16.

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE.

J Clin Invest. 2005 Jan;115(1):94-101.

17.

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J.

Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22.

18.
19.

KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.

Neiswender JV, Kortum RL, Bourque C, Kasheta M, Zon LI, Morrison DK, Ceol CJ.

Cancer Res. 2017 Nov 1;77(21):5820-5830. doi: 10.1158/0008-5472.CAN-17-0473. Epub 2017 Sep 25.

20.

BRAF fusions identified in melanomas have variable treatment responses and phenotypes.

Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL.

Oncogene. 2019 Feb;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7. Epub 2018 Sep 25.

PMID:
30254212

Supplemental Content

Support Center